EP1675873A1 - Correlation du ratio taux de fucose / taux de galactose d'anticorps anti rhesus d et anti hla-dr avec l'activite adcc - Google Patents

Correlation du ratio taux de fucose / taux de galactose d'anticorps anti rhesus d et anti hla-dr avec l'activite adcc

Info

Publication number
EP1675873A1
EP1675873A1 EP04805250A EP04805250A EP1675873A1 EP 1675873 A1 EP1675873 A1 EP 1675873A1 EP 04805250 A EP04805250 A EP 04805250A EP 04805250 A EP04805250 A EP 04805250A EP 1675873 A1 EP1675873 A1 EP 1675873A1
Authority
EP
European Patent Office
Prior art keywords
antibodies
antibody
fucose
galactose
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04805250A
Other languages
German (de)
English (en)
French (fr)
Inventor
Nicolas Bihoreau
Christophe De Romeuf
Sylvie Jorieux
Emmanuel Nony
Dominique Bourel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB Biotechnologies SAS
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LFB SA filed Critical LFB SA
Publication of EP1675873A1 publication Critical patent/EP1675873A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Definitions

  • the present invention relates to compositions of monoclonal antibodies having a high ADCC activity and whose ratio fucose rate / galactose rate of the glycan structures present on their glycosylation sites of the Fc region, is less than or equal to 0.6 .
  • the invention also relates to pharmaceutical compositions comprising said monoclonal antibodies having a strong effector activity.
  • Passive immunotherapy very widespread, is based on the administration of antibodies, in particular immunoglobulins of the IgG type, directed against a given cell or substance. Passive immunotherapy using monoclonal antibodies has given encouraging results. However, if the use of monoclonal antibodies has several advantages, such as an assurance of product safety as regards the absence of infectious contamination, it may however prove difficult to obtain an effective monoclonal antibody.
  • Immunoglobulin type G are heterodimers consisting of 2 heavy chains and 2 light chains, linked together by disulfide bridges. Each chain consists, in the N-terminal position, of a specific variable part of the antigen against which the antibody is directed, and in the C-terminal position, of a constant part, mediating the effector properties of the antibody. .
  • variable parts and the CHj and CL domains of the heavy and light chains forms the Fab parts, which are connected to the Fc region (constant part of the heavy chain) by a region of exceptional flexibility (hinge region). thus allowing each Fab to bind to its antigenic target while the Fc region remains accessible to effector molecules such as Fc ⁇ R receptors and Clq.
  • the Fc region consists of 2 globular domains named CH 2 and CH 3 .
  • the 2 heavy chains interact closely at the level of the CH 3 domains while at the level of the CH 2 domains, the presence, on each of the 2 chains, of a biantennary N-glycan of lactosaminic type, linked to Asn 297, contributes to a separation of the 2 domains.
  • the antibody if the antibody is strongly fucosylated, it must be strongly galactosylated to have optimal effector activity. Conversely, if the antibody is weakly fucosylated, the level of galactose present must be such that the ratio of fucose / galactose level is less than 0.6 but preferably less than 0.5 or even less than 0.4 for have optimal effector activity.
  • the invention relates to a process for the preparation of a chimeric, humanized or human monoclonal antibody having a strong effector activity, characterized in that it comprises the following stages: a) production and purification of monoclonal antibodies obtained from different sources, in particular cells, plants or non-human animals, possibly genetically modified or transformed, b) measurement of the fucose rate and the galactose rate of the glycan structures carried by the glycosylation sites of the region Fc of said antibodies, c) selection of antibodies in which the fucose / galactose rate ratio is less than or equal to 0.6, preferably 0.5 or 0.4.
  • a monoclonal antibody is intended to mean a composition comprising monoclonal antibodies having an identical primary structure, except for the small proportion of antibodies having naturally occurring mutations, identical specificity and post-translational modifications, in particular modifications of glycosylation. , which can vary from one molecule to another.
  • the expressions “monoclonal antibody” or “composition of a monoclonal antibody” are synonymous.
  • the monoclonal antibodies of the invention can be prepared using conventional methods, such as the production of hybridomas as described by Kohler and Milstein (1975), the immortalization of human B cells by the Epstein-Barr virus (EBN), or more recent, such as phage display technology, the use of a combinatorial library of human antibodies or transgenic animals, in particular the Xenomouse® mouse; monoclonal antibodies can also be prepared by molecular engineering, in particular to chimerize or humanize the antibodies.
  • the analysis of glycans can be carried out for example by HPCE-LIF (High-Performance Capillary Electrophoresis with Laser-Induced Fluorescence), or by any other method of analysis of glycans known to man. of career.
  • the method according to the invention makes it possible to obtain a monoclonal antibody having a strong effector activity, and more particularly a strong functional activity of the ADCC type.
  • the term effector is understood to mean the biological activities attributable to the Fc region of an antibody. Examples of these effector functions include, but are not limited to, ADCC activity (Antibody-Dependent Cell-mediated Cytotoxicity), CDC activity (Complement-Dependent Cytotoxicity), phagocytosis activity, endocytosis activity or the induction of cytokine secretion.
  • strong effector activity is meant an effector activity at least 20 times, 50 times, 60 times, 70 times, 80 times, or 90 times, and preferably up to 100 times, or preferably 500 times greater than 1 effector activity of antibodies with the same specificity but with a fucose / galactose rate ratio greater than 0.6.
  • the fucose / galactose rate ratio is between the values 0.6 and 0.3, preferably between 0.5 and 0.35.
  • the galatose rate can be between 70 and 99%. If the fucose rate is between 20% and 35%, the galatose rate is between 55% and 70% or even between 60% and 99%.
  • the value of the “ratio less than or equal to 0.6” also means a value greater than 0.6 of a few hundredths of a unit, for example 4 to 5 hundredths.
  • the antibodies obtained by the process according to the invention are produced in cells genetically modified by the introduction of at least one vector allowing the expression of the antibodies, these cells being eukaryotic or prokaryotic cells, in particular cells of mammals, insects, plants, bacteria or yeasts.
  • the antibody obtained is a human immunoglobulin of the IgG type.
  • these cells can be genetically modified by the introduction of at least one vector allowing the expression of at least one polypeptide having a glycosyltransferase activity.
  • this glycosyltransferase activity is a galactosyltransferase activity, and in particular a beta (1, 4) -galactosyltransferase or beta (1, 3) -galactosyltransferase activity.
  • polypeptide having galactosyltransferase activity means any polypeptide capable of catalyzing the addition of a galactose residue from UDP -galactose to the residue of GlcNAc in the non-reducing position of an N-glycan.
  • vector allowing the expression of a polypeptide having a beta (1,4) -galactosyltransferasic activity means any vector comprising a polynucleotide allowing the expression of a polypeptide capable of synthesize the disaccharide motif Galbeta (1,4) -GlcNac, this polynucleotide which can come from species such as man, mouse, hamster, cow, sheep, goat, pig, horse, rat, monkey, rabbit, chicken for example.
  • Such sequences such as for example NM 001497, AB 024434, NM 003780, BC 053006, XM 242992, NM 177512, this list not being exhaustive, are available in nucleotide and / or protein sequence banks such as Genbank.
  • vector allowing the expression of a polypeptide having a beta (1,3) -galactosyltransferasic activity means any vector comprising a polynucleotide allowing the expression of a polypeptide capable of synthesizing the motif disaccharide Galbeta (1, 3) -GlcNac, this polynucleotide which can come from species like man, mouse, hamster, cow, sheep, goat, pig, horse, rat, monkey, rabbit, chicken for example.
  • sequences coding for a beta (1, 3) -galactosyltransferase originating from species such as man, mouse, hamster, cow, sheep, goat, pig, horse, rat, monkey , rabbit, chicken for example are particularly suitable.
  • species such as man, mouse, hamster, cow, sheep, goat, pig, horse, rat, monkey , rabbit, chicken for example.
  • sequences are available on Genbank, such as for example NM020981, AB084170, AY043479, this list is not exhaustive.
  • glycosylation site of the Fc region of the antibodies generally means the two residues of Asn297 according to the Kabat numbering (Kabat database, http://immuno.bme.nwu.edu), but the invention also relates to antibodies whose amino acid sequences have been modified.
  • the cells also have an activity relating to the synthesis and / or transport of GDP-fucose and / or the activity of an enzyme involved in the addition of fucose to the oligosaccharide of the site of glycosylation of the antibodies decreased or deleted.
  • the enzyme involved in the synthesis of GDP-fucose is GMD (GDP-D-mannose 4,6-dehydratase), Fx (GDP-keto-6-deoxymannose 3,5-epimerase, 4-reductase ) or the GFPP (GDP-beta-L-fucose pyrophosphorylase), this list is not exhaustive.
  • the enzyme involved in. the addition of fucose is a fucosyltransferase.
  • the protein involved in the transport of GDP-fucose can advantageously be human GDP-fucose tansporter 1.
  • the fucose and galactose levels measured in step b) give a ratio greater than 0.6, to defucosylate and / or to add galactose residues to the antibodies before step c), so that the said ratio becomes less than 0.6 but preferably less than 0.5 and even less than 0.4 in order to increase the functional activity of the antibodies.
  • This defucosylation can be carried out by adding a fucosidase to the medium containing the antibody, which can be the preservation medium.
  • galactose residues can be carried out by any suitable means including the addition of a galactosyltransferase in the medium containing the antibody or in a solution containing the antibody and a donor substrate such as UDP -galactose, by example.
  • the cells used to implement the method according to the invention come from animal or human cell lines, these lines being selected in particular from the rat myeloma lines, in particular YB2 / 0 and IR983F, from human myeloma such as Namalwa or any other cell of human origin such as PERC6, CHO lines, in particular CHO-K, CHO-LeclO, CHO-Lecl, CHO Pro-5, CHO dhfr-, CHO Lecl3, or other lines chosen from Wil-2 , Jurkat, Nero, Molt-4, COS-7, 293-HEK, BHK, K6H6, ⁇ SO, SP2 / 0-Ag 14 and P3X63Ag8.653.
  • human myeloma lines such as Namalwa or any other cell of human origin such as PERC6, CHO lines, in particular CHO-K, CHO-LeclO, CHO-Lecl, CHO Pro-5, CHO dhf
  • the antibody is an anti-Rhesus D (anti-D), anti-CD, anti-tumor, anti-virus, anti-CD20 or an anti-HLA-DR, more particularly among the antibodies of Table 0 below.
  • Table 0 Name and brand Target company commercial indication of the antibody Edrecolomab Centocor anti Ep-CAM colorectal cancer PANOREX Rituximab Idea anti CD20 B cell lymphoma RITUXAN Licensed to thrombocytopenia purpura Genentech / Hoffman rock Trastuzumab Genentech anti HER2 ovarian cancer HERCEPTIN Licensed to Hoffman roche / Immunogen Palivizumab Medimmune RSV SYNAGIS Licensed to Abott Alemruzumab BTG anti CD52 leukemia CAMPATH Licensed to Schering ibritumomab IDEC anti CD20 NHL tiuxetan Licensed to Schering ZEVALIN Cetuximab Merck / BMS / anti
  • Bevacizumab Genentech / anti VEGFR cancer A VASTIN Hoffman la roche Epratuzumab Immumedics / anti CD22 cancers: Amgen non-Hogkinian lymphoma Hu M195Mab Protein Design Anti CD33 cancers Labs MDX-210 hrrmuno-Designed ⁇ D cancers BEC2 molecules hnclone anti GD3 cancers Mitumomab Oregovomab Altarex anti CA125 ovarian cancer OVAREX Himalayan Melomim Komaroma -2971 ABX-EGF Abgenix EGF cancers
  • IDEC-114 ⁇ DEC inhibition of non-Hodgkin's lymphoma ProteinC
  • a second object of the invention is to provide a method for increasing the effector activity, in particular the ADCC activity, of a composition of immunologically functional molecules, comprising increasing the level of galactose and / or decreasing the level of fucose of the composition of molecules.
  • immunologically functional molecules is intended to denote molecules capable of reacting to any contact with any immunogen by manifesting an immunological capacity. These molecules can present in the native state a good effector activity, for example ADCC, or a poor effector activity. They have an Fc region comprising a glycosylation site.
  • these functionally immunplogic molecules are preferably antibodies, advantageously monoclonal or polyclonal.
  • the molecules may have a high level of fucose in the native state. More particularly, it is advantageous in this case to effect an increase in the galactose level of these molecules or antibodies.
  • the reduction in the rate of fucose is achieved by de-fucosylation of the molecules of the composition by the action of a fucosidase.
  • This de-fucosylation can be carried out by an ⁇ 1.6 fucosidase. Fucosidases extracted from kidney of bovine or Charonia lampas have this specificity.
  • the increase in the level of galactose of the molecules of the composition is due to a galactosylation of the composition by the action of a galactosyltransferase.
  • both enzymes allowing de-fucosylation and enzymes allowing galactosylation are made to act.
  • the composition of immunologically functional molecules can be purified by means of a series of chromatographies on lectins which enrich the composition with weakly fucosylated antibodies and / or with strongly galactosylated antibodies.
  • the solution comprising the composition of immunologically functional molecules, which are advantageously antibodies is passed over a lectin column (for example an LA-LCA, or LA-AAL, Shimadzu Corporation column) connected to an HPLC system.
  • a lectin column for example an LA-LCA, or LA-AAL, Shimadzu Corporation column
  • the solution is separated into a non-adsorbed fraction and an adsorbed fraction.
  • An analysis of the glycans of the non-adsorbed and adsorbed fractions is carried out: the oligosaccharides, cleaved from the protein part by enzymatic action, are labeled with APTS and are separated by HPCE-LIF and quantified. .
  • the areas of the peaks are calculated: the antibodies possessing glycans devoid of fucose can thus be separated and selected.
  • the selected fraction is then passed (which can be obtained from the non-adsorbed fraction or from the adsorbed fraction) either on a hydrophobic column of the Phenyl-5PW type (prepared by Tosoh Corporation) or on a second lectin column (LA-RCA 120 or LA- WGA, Seikagaku America). It is thus possible to precisely select the fractions whose ratio fucose rate / galactose rate is less than or equal to 0.6.
  • a third subject of the invention is a cell, preferably derived from the YB2 / 0 cell line, into which at least one vector coding for an antibody molecule is introduced, said cell producing a monoclonal antibody having a ratio of fucose / galactose level of the oligosaccharides of the glycosylation site of the Fc region less than or equal to 0.6. Preferably, this ratio is less than 0.5 or even 0.4. In a preferred aspect of the invention, this ratio is between 0.6 and 0.3.
  • this cell is transfected with an expression vector coding for a galactosyltransferase, in particular for a beta (1; 4) - galactosyltransferase or a beta (1,3) -galactosyltransferase.
  • this cell expresses or over-expresses a recombinant galactosyltransferase.
  • the YB2 / 0 line naturally expresses galactosyltransferases from the beta (1,4) and beta (1,3) family.
  • this cell line is known to produce antibodies having a low level of fucose (WO 01/77181, LFB).
  • the cell according to the invention has the advantage of over-expressing the galactosyltransferase, which has the effect of varying the fucose / galactose rate ratio of the antibodies produced by the modified cell compared to the antibodies produced by the line. not modified. Consequently, since the antibody is naturally weakly fucosylated, an increase in its galactose level further lowers its fucose / galactose rate ratio, which has the effect of further optimizing its ADCC activity.
  • the galactosyltransferase is coded by a sequence originating from man, mouse, hamster, cow, sheep, goat, pig, horse, rat, monkey, rabbit or chicken , this list is not exhaustive. More particularly, the coding sequence is the sequence NM 001497, AB 024434, NM 003780, BC 053006, XM 242992 or NM 177512.
  • the invention also relates to a process for preparing monoclonal antibodies whose glycan structures carried by the glycosylation site of the Fc region have a fucose / galactose rate ratio less than or equal to 0.6, preferably less than 0.5 or even 0.4 comprising the culture of the cell previously described in a culture medium and under conditions allowing the expression of said vectors.
  • the invention relates to therapeutic antibodies having a strong effector activity, capable of being obtained from the methods described above, or also obtained from the methods described, these antibodies being characterized in that they present on their glycosylation site of the Fc region, glycan structures having a fucose / galactose rate ratio of less than 0.6, preferably less than 0.5 or even 0.4.
  • they are therapeutic monoclonal antibodies capable of being obtained from the preceding method, said antibodies having an enhanced ADCC activity, for example monoclonal anti-D having an equal or greater ADCC activity. to that of polyclonal antibodies.
  • This enhanced ADCC activity is at least equal but preferably greater than that of the polyclonal or monoclonal therapeutic antibody (of the same specificity) expressed in a CHO DG44 or DxB 11 line.
  • IgG for example IgG1 or IgG3, chimeric, humanized or human or IgG having a human Fc region.
  • these antibodies are human IgG or any chimeric molecule comprising a human Fc region.
  • the invention relates to a pharmaceutical composition comprising an antibody previously described.
  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising at least 50%, preferably 60%, 70%, 80% or even 90% or 99% of a monoclonal or polyclonal antibody whose glycan structures carried by the site of glycosylation of the Fc region have a fucose / galactose rate ratio of less than 0.6, preferably less than 0.5 or even 0.4. So preferential, the ratio is between the values 0.6 and 0.3, and more particularly between 0.5 and 0.35.
  • compositions according to the invention preferably comprise an antibody directed against a normal non-ubiquitous antigen, in particular a Rhesus factor, such as the Rhesus factor (D) of the human red blood cell, or an antigen of a pathological cell or of a pathogenic organism for humans, especially against a cancer cell antigen.
  • a Rhesus factor such as the Rhesus factor (D) of the human red blood cell
  • the antibodies are more preferably IgGs.
  • Another subject of the invention relates to the use of an antibody according to the invention for the preparation of a medicament intended for the treatment of alloimmunization, in particular hemolytic disease of the newborn.
  • Another subject of the invention relates to the use of an antibody according to the invention for the preparation of a medicament intended for the treatment of autoimmune diseases, cancers and infections by pathogenic agents, in particular for the treatment of diseases escaping the immune response in particular chosen from Sézary Syndrome, solid cancers, in particular whose antigenic targets are weakly expressed, in particular breast cancer, pathologies linked to the environment targeting in particular people exposed to polychlorinated biphenyls , infectious diseases, especially tuberculosis, chronic fatigue syndrome (CFS), parasitic infections such as schistosomules, and viral infections.
  • pathogenic agents in particular for the treatment of diseases escaping the immune response in particular chosen from Sézary Syndrome, solid cancers, in particular whose antigenic targets are weakly expressed, in particular breast cancer, pathologies linked to the environment targeting in particular people exposed to polychlorinated biphenyls , infectious diseases, especially tuberculosis, chronic fatigue syndrome (CFS), parasitic infections such as schistosomules, and viral infections
  • the antibody according to the invention can be used for the preparation of a medicament intended for the treatment of cancers of HLA class II positive cells such as melanomas, acute lymphoid leukemias of B and T cells, chronic myeloid leukemias and acute, Burkitt's lymphoma, Hodgkin's lymphoma, T-cell lymphomas and non-Hodgkin's lymphomas.
  • HLA class II positive cells such as melanomas, acute lymphoid leukemias of B and T cells, chronic myeloid leukemias and acute, Burkitt's lymphoma, Hodgkin's lymphoma, T-cell lymphomas and non-Hodgkin's lymphomas.
  • the antibodies of the invention can be selected from the antibodies listed in Table 0.
  • the antibody is an anti-HLA-DR or an anti-CD20.
  • the antibody according to the invention is used for the manufacture of a medicament intended to induce the expression of at least one cytokine chosen from IL-1 ⁇ , IL-1 ⁇ , IL-2 , IL-3, IL-4, IL-5, IL-6, IL-12, IL-18, IL-21, TGF ⁇ 1, TGF ⁇ 2, TNF ⁇ , TNF ⁇ , IFN ⁇ , and IP 10 by natural effector cells of the immune system , said medicament being useful in particular for the treatment of cancer and viral, bacterial or parasitic infections.
  • cytokine chosen from IL-1 ⁇ , IL-1 ⁇ , IL-2 , IL-3, IL-4, IL-5, IL-6, IL-12, IL-18, IL-21, TGF ⁇ 1, TGF ⁇ 2, TNF ⁇ , TNF ⁇ , IFN ⁇ , and IP 10
  • the antibody according to the invention is used for the manufacture of a medicament intended for the treatment of patients having one of the CD16 polymorphisms, in particular N / F158 or F / F158, in particular patients in therapeutic failure with currently available antibodies or experiencing undesirable side effects.
  • the invention also relates to a process for preparing a chimeric, humanized or human monoclonal antibody having a low effector activity, in particular a low functional activity of ADCC type, characterized in that it comprises the steps following: a) production and purification of monoclonal antibodies obtained from different sources, in particular cells, plants or non-human animals, possibly genetically modified or transformed, b) measurement of the rate of fucose and of galactose of the glycan structures carried by the glycosylation site of the Fc region of said antibodies, c) selection of antibodies in which the fucose / galactose rate ratio is greater than 0.6, preferably greater than 1.2.
  • the definitions of the effector activity of a monoclonal antibody are the same as those given above.
  • weak effector activity means an effector activity at least 20 times, 50 times, 60 times, 70 times, 80 times, or 90 times, and preferably up to 100 times, or preferably 500 times lower than the effector activity, in particular the functional activity of the ADCC type of antibodies with the same specificity but whose ratio of fucose rate / galactose rate is less than 0.6.
  • the invention therefore relates to antibodies having a low ADCC activity, and the compositions comprising them, characterized in that their glycosylation site (Asn 297) of the Fc region exhibits a fucose / galactose rate ratio greater than 1.2.
  • These antibodies are useful for preparing drugs to treat and / or prevent autoimmune diseases, including immunological thrombocytopenic purpura (ITP), alloimmunizations, transplant rejection, allergies, asthma, dermatitis, hives, erythema, and inflammatory diseases.
  • ITP immunological thrombocytopenic purpura
  • the antibodies are produced in genetically modified cells by the introduction of at least one vector allowing the expression of said antibodies, said cells being eukaryotic or prokaryotic cells, in particular mammalian cells, insects, plants, bacteria or yeast.
  • the cells are genetically modified by the introduction of at least one vector allowing the expression of at least one polypeptide having a glycosyltransferase activity, preferably a fucosyltransferase activity and in particular 1, 6-fucosyltransferase.
  • the cells have an activity relating to the synthesis and / or transport of UDP -galactose and / or the activity of an enzyme involved in the addition of galactose to l oligosaccharide from the site of antibody glycosylation is decreased or deleted.
  • this enzyme involved in the addition of galactose is a ⁇ 1,4-galactosyltransferase.
  • the cells have both a glycosyltransferase activity, preferably a fucosyltransferase activity and an activity relating to the synthesis and / or transport of UDP-galactose and / or the activity of an enzyme involved in the addition of galactose to the oligosaccharide from the decreased or deleted antibody glycosylation site.
  • a glycosyltransferase activity preferably a fucosyltransferase activity
  • an activity relating to the synthesis and / or transport of UDP-galactose and / or the activity of an enzyme involved in the addition of galactose to the oligosaccharide from the decreased or deleted antibody glycosylation site preferably a fucosyltransferase activity and an activity relating to the synthesis and / or transport of UDP-galactose and / or the activity of an enzyme involved in the addition of galactose to the oligosaccharide from the decreased or deleted antibody glyco
  • the measured ratio is less than 0.6, fucosylated and / or removes galactose residues from said antibody before step c ), so that the fucose / galactose rate ratio becomes greater than 0.6.
  • the de-galactosylation is carried out by the addition of a galactosidase in the medium containing the antibody.
  • the addition of fucose residues is carried out by the addition of a fucosyltransferase in the medium containing the antibody.
  • the antibody is a human immunoglobulin of the IgG type.
  • the antibody is directed against a CD, a marker for differentiation of human blood cells or against a pathogenic agent or its toxin listed as being particularly dangerous in cases of bioterrorism, in particular Bacillus anthracis, Clostridium botulium, Yersinia pestis, Variola major, Francisella tularensis, Filoviruses, Arenaviruses, Brucella species, Clostridium perfringens, Salmonella, E.coli, Shigella, Coxiella burnetii, castor toxin, Rickettsia, Viral encephalitis viruses, Vibrio cholerae or Hantavirus.
  • Another subject of the invention relates to a method for decreasing the activity of a composition of immunologically functional molecules, comprising increasing the level of fucose and / or decreasing the level of galactose of said composition.
  • the immunologically functional molecules are monoclonal or polyclonal antibodies.
  • the increase in the rate of fucose is due to a fucosylation of said composition by the action of a rucosyltransferase, preferably an ⁇ 1,6-fucosyltransferase.
  • the decrease in the galactose level of said composition is due to a de-galactosylation of the composition by the action of a galactosidase, preferably one or more ⁇ -galactosidase.
  • an object of the invention relates to an antibody composition capable of being obtained from the methods according to the invention described above, or an antibody composition obtained from one of these methods .
  • a further object of the invention is the use of this antibody composition for the preparation of a medicament intended for the treatment and / or prevention of autoimmune diseases and in particular ITP, of alloimmunization, transplant rejection, allergies, asthma, dermatitis, hives, erythema, or inflammatory diseases, this list is not exhaustive.
  • the invention relates to a method for controlling the activity of a composition of immunologically functional molecules, comprising the regulation of the fucose rate / galactose rate ratio of the oligosaccharides of the glycosylation site of the Fc region of the antibodies.
  • Figure 1 Glycan structures present on the glycosylation site of the Fc region of different anti-Rh (D) antibodies.
  • This figure represents the percentages of the different glycan forms carried by the residues Asn297 of 3 anti-Rh (D) antibodies: anti-D IgGl of WinRho (black histograms), monoclonal antibody EMAB2 (white histograms) and Anti- Dl (hatched histograms) .
  • Figure 2 Correlation line between the fucose / galactose rate ratio and the ADCC activity of anti-Rh (D) antibodies.
  • FIG. 3 Effect of galactose level on the ADCC activity of anti-Rh (D) polyclonal antibodies.
  • This figure represents the percentage of lysis of Rh (D +) red blood cells induced by polyclonal anti-Rh (D) antibodies equal or not equal (Control) in the presence of polyvalent IgG (Tegeline, LFB) at the concentration of 0 , 5 and 2.5 mgml.
  • FIG. 4 CD 16 activation of anti-Rh (D) degalactosylated monoclonal antibodies. This figure represents the% of CD 16 activation induced by the presence of anti-Rh (D) EMAB2 and HHO1 monoclonal antibodies, degalactosylated (white histograms) or not (control, black histograms).
  • FIG. 5 CD 16 activation of galactosylated anti-Rh (D) monoclonal antibodies. This figure represents the CD16 activation induced by the anti-Rh (D), EMAB2 and EMAB3 monoclonal antibodies, before (control, black histograms) and after galactosylation in vitro by bovine ⁇ 1, 4-galactosyltransferase (white histograms).
  • Figure 6 Clearance curves for radiolabelled red cells, sensitized or not by anti-Rh (D) antibodies.
  • This figure represents the monitoring of the radioactivity, expressed in%, contained in the blood of volunteers to which a volume of red blood cells labeled with Cr 51 has been re-injected, either not sensitized ( ⁇ ,) or sensitized by the therapeutic preparation of Rhophylac polyclonal antibodies.
  • TM (•) or by the monoclonal antibody EMAB2 (", A, ⁇ ).
  • the antibody EMAB2 was tested in 3 volunteers (008, 009 and 010).
  • Figure 7 Effect of degalactosylation of anti-HLA DR monoclonal antibodies expressed in cell lines YB2 / 0 and CHO-DG44 on CD16 activation.
  • This figure represents the quantity, expressed in pg / ml, of Il-2 secreted by Jurkat CD 16 cells whose CD 16 receptor has been activated, in the presence of Raji cells carrying on their membrane molecules of HLA DR, by chimeric anti-HLA DR antibodies, native (solid lines) or degalactosylated (dotted lines).
  • Example 1 Correlation between the fucose / galactose rate ratio and the ADCC activity of a cohort of anti-Rh (D) antibodies.
  • the monoclonal antibodies are derived from the transformation by EBV, of B lymphocytes of a negative Rh (D) human donor, immunized with red cells carrying the Rh (D) antigen. From this transformation, 2 clones were selected: 1) one of the clones was fused with human / mouse heteromyeloma K6H6-B5; from this fusion was selected the HHOl clone. 2) from the other clone, the RNA encoding the anti-Rh (D) antibody were extracted for the preparation of an expression vector for the heavy chain and the light chain of the antibody.
  • This expression vector was used to transfect, on the one hand the cell line YB2 / 0 giving rise to the antibodies EMAB1, EMAB2, EMAB3 and EMAB4 and, on the other hand, the following CHO lines: DG44, Kl and Lecl3 which synthesize Anti-Dl, Anti-D2 and Anti-D3 antibodies, respectively.
  • DG44 CHO lines
  • Kl Kl and Lecl3 which synthesize Anti-Dl, Anti-D2 and Anti-D3 antibodies, respectively.
  • the oligosaccharides thus obtained are either labeled directly with a fluorochrome, the APTS (1-ammo-pyrene-3,6,8-trisulfonate) or subjected to the action of specific exoglycosidases before labeling by the APTS. Then the labeled oligosaccharides are injected into an N-CHO capillary and separated and quantified by capillary electrophoresis with laser-induced fluorescence detection (HPCE-LIF).
  • HPCE-LIF laser-induced fluorescence detection
  • the evaluation of the fucose level is carried out either by the addition of the isolated fucosylated forms, or more specifically after the simultaneous action of neuraminidase, ⁇ -galactosidase and N-acetylhexosaminidase, making it possible to obtain, on the electropherogram, 2 peaks corresponding to the pentasaccharide [Glc ⁇ ac2-Man3] fucosylated or not.
  • the galactose level is calculated by adding the percentages of the oligosaccharide forms containing galactose in the terminal position.
  • the formula used is as follows: Galactose level - [(G1 + G1B + G1F + G1FB) + 2x (G2 + G2F + G2B + G2FB)]
  • the ratio of fucose / galactose rate is obtained by dividing the fucose rate by the galactose rate, the rates being calculated as described above.
  • ADCC Antibody-Dependent Cell-mediated Cytotoxicity
  • red cells of a RhD (+) globular concentrate are treated with papain
  • Effector cells are isolated from a pool of at least 3 buffy coats, by centrifugation on FicoU
  • a microtiter plate (96 wells) is deposited per well: 100 ⁇ l of a dilution of purified anti-Rh (D) antibody (from 9.3 to 150 ng / ml), 25 ⁇ l of Rh (D +) papain red blood cells (i.e. 1.10 6 ), 25 ⁇ l of effector cells (ie 2.10) and 50 ⁇ l of polyvalent IgG (Tegeline, LFB) at the usual concentrations of 2 and 10 mg / ml. Dilutions are made in MDM 0.25% fetal calf serum (SNF).
  • SNF fetal calf serum
  • the plates are centrifuged, then 'the released hemoglobin in the supernatant was measured via its peroxidase activity in the presence of a chromogenic substrate, 2,7 diaminofluorene (DAF).
  • DAF 2,7 diaminofluorene
  • the results are expressed as a percentage of lysis, 100% corresponding to the total lysis of erythrocytes in ⁇ H 4 C1 (control 100%) and 0% to the reaction mixture without antibody (control 0%).
  • the specific lysis is calculated as a percentage according to the following formula:
  • the immunopurified polyclonal antibodies are dialyzed against the hydrolysis buffer (50 mM sodium acetate, pH 5.5 containing 4 mM calcium chloride).
  • the antibodies are desialylated and degalactosylated by incubation in the presence of 5 mU of neuraminidase (EC 3.2.1.18) from Vibrio cholerae (Calbiochem) and 9 mU of ⁇ -galactosidase (EC 3.2.1.23) produced by E. Coli (Roche).
  • control consists of the same preparation of antibody treated as indicated above but in the absence of neuraminidase and of ⁇ -galactosidase. After 24 hours of incubation at 37 ° C, the antibodies are stored at 4 ° C.
  • the antibodies generated in this example are separated into two fractions; One of the fractions is used for glycan analysis . and the other fraction is reserved for measuring ADCC activity.
  • the procedure consists in desalting on a Sephadex-G25 column the fraction of polygalonal anti-Rh (D) degalactosylated antibodies in order to remove the salts but also the free dares which could be present in the preparation.
  • D polygalonal anti-Rh
  • the glycans are released by the action of endoglycosidase PNGase F (Glyko).
  • PNGase F endoglycosidase F
  • the sample is subjected to the simultaneous action of sialidase and fucosidase or of sialidase, ⁇ -galactosidase and N-acetylhexosaminidase, respectively, before labeling with the APTS. Then the labeled oligosaccharides are injected onto an N-CHO capillary and separated and quantified by capillary electrophoresis with laser-induced fluorescence detection (HPCE-LIF). 3. Measurement of ADCC activity.
  • the measurement of the ADCC activity of the polyclonal antibodies before and after treatment with ⁇ -galactosidase is carried out according to the method described in Example 1.
  • the glycans of the Fc region of polyclonal anti-Rh (D) antibodies have a residual galactose level of 17.7% and a fucose level equal to 68.5%.
  • the fucose / galactose rate ratio of degalactosylated polyclonal antibodies is therefore equal to 3.8.
  • the percentage of ADCC activity of anti-Rh (D) degalactosylated polyclonal antibodies compared to control antibodies, that is to say having undergone the same incubation but in the absence of neuraminidase and ⁇ -galactosidase, are presented in the table. II.
  • the decrease in the ADCC activity of the polygalonal antibodies degalactosylated compared to the control antibodies is all the more important as the quantity of antibodies is low.
  • the decrease in activity of degalactosylated polyclonal antibodies is greater in the presence of a concentration of polyvalent IgG of 2.5 mg / ml.
  • EXAMPLE 3 Measurement of the Activation of the CD16 Receptor Induced by the Degalactosylated Anti-Rh (D) Monoclonal Antibodies 1. Degalactosylation of the Anti-Rh (D) Monoclonal Antibodies
  • the antibodies are dialyzed against the hydrolysis buffer (50 mM sodium acetate, pH 5.5 containing 4 mM calcium chloride).
  • the antibodies are desialylated and degalactosylated by an incubation in the presence of 5 mU of neuraminidase (EC 3.2.1.18) of Vibrio cholerae (Calbiochem) and 9 mU of ⁇ -galactosidase (EC 3.2.1.23) produced by E.coli (Roche).
  • the control designated by the name of “control”, consists of the same preparation of antibody treated as indicated above but in the absence of neuraminidase and of ⁇ -galactosidase. After 24 hours of incubation at 37 ° C, the antibodies are stored at 4 ° C.
  • the antibodies generated in this example are separated into two fractions; one of the fractions is used for glycan analysis and the other fraction is reserved for the measurement of functional activity.
  • the Jurkat CD 16 cell activation test measures the secretion of interleukin-2 (IL-2) induced by the binding of antibody Fc to CD 16 (Fc ⁇ RIIIA) after binding of the Fab to its antigen, present on the target cell.
  • IL-2 interleukin-2
  • Fc ⁇ RIIIA antibody Fc to CD 16
  • the level of IL-2 secreted by Jurkat CD 16 cells is proportional to the activation of the CD16 receptor.
  • a 96-well microtiter plate 50 ⁇ l of antibody dilutions are successively deposited, 50 ⁇ l of a red blood cell suspension at 6.10 5 / ml, 50 ⁇ l of a suspension of Jurkat CD 16 cells at 1.10 6 / ml and 50 ⁇ l of a 40 ng / ml PMA solution. All dilutions were carried out in EMDM culture medium containing 5% SNF.
  • the microtiter plate After 16 hours of incubation at 37 ° C and 7% CO 2, the microtiter plate is centrifuged and the amount of IL-2 contained in the supernatant is assayed by a commercial kit (Duoset, R&D). The levels of secreted IL-2 are expressed in pg / ml. The results are expressed as a percentage of CD16 activation, the level of IL-2 secreted in the presence of the control monoclonal antibody being considered equal to 100%.
  • the monoclonal antibody EMAB2 is completely degalactosylated while the antibody HHOl still contains 17.3% of monogalactosylated forms.
  • the fucose / galactose rate ratio of the EMAB2 and HHOl antibodies therefore becomes much greater than 0.6.
  • the degalactosylated anti-Rh (D) monoclonal antibodies exhibit a much reduced CD 16 activation compared to the control antibodies (FIG. 4).
  • the monoclonal antibodies EMAB2 and HHO1 show a decrease in their capacity to induce CD16 activation by 52 and 47%, respectively.
  • the antibodies are dialyzed against 50 mM HEPES buffer, pH 7.20.
  • the reaction mixture consists of the solution of monoclonal antibodies to which are added 10 mM MnC12, 20 mM UDP-galactose and 40 mU of bovine ⁇ 1,4-galactosyltransferase (Calbiochem). After incubation at 37 ° C for 24 hours, the tubes are stored at 4 ° C before use.
  • the control consists of the same antibody incubated under the same conditions except for the absence of UDP-Gal in the reaction medium.
  • the antibodies generated in this example are separated into two fractions; one of the fractions is used for glycan analysis and the other fraction is reserved for the measurement of ADCC activity.
  • the monoclonal antibodies are immobilized in the wells of a microtiter plate. After 20 minutes of heating at 100 ° C. to denature the IgG molecules in order to make the N-glycans of the Fc region accessible, the wells are incubated for 2 h. at room temperature and with gentle stirring in the presence of a biotinylated RCAi solution (Nector). After washing to remove the unreacted lectin, streptavidin-peroxidase is added to each well, incubated for 1 h and the fixed lectin is measured at 492 nm after addition of O-phenylenediamine.
  • the quantity of antibody fixed in the wells of the microtitration plate is measured by an anti-human IgG antibody labeled with peroxidase. Then the quantity of lectin fixed is corrected by the quantity of antibody fixed in the microtiter wells.
  • the monoclonal antibodies described in the present example are anti-Rh (D) antibodies having the same primary sequence and produced by the YB2 / 0 cell. They differ in their functional activity, in connection with their rate of fucosylation in ⁇ 1, 6 which is 25% for EMAB2 and 53% for EMAB3.
  • CD16 activation induced by the monoclonal antibodies EMAB2 and EMAB3 is increased by 10 and 54%, respectively (Fig. 5).
  • the anti-Rh (D) monoclonal antibody EMAB2 was evaluated in a phase I clinical trial in order to compare the clearance of red cells sensitized by this antibody with that of red cells sensitized by Rhophylac TM, a therapeutic preparation of anti-Rh polyclonal antibodies. (D) used clinically.
  • the red cells of healthy volunteers are labeled ex-vivo with chromium 51 ( 51 Cr) and sensitized, that is to say incubated, in the presence of anti-Rh (D) antibodies, EMAB2 or Rhophylac TM, to obtain a level saturation of 25% of the antigenic sites before being re-injected into the volunteers.
  • the disappearance in the blood circulation of the red cells labeled with 51 Cr was followed by measurement of the radioactivity with the gamma counter on blood samples taken at 3, 15, 30 minutes and 1, 2, 4, 6, 8, 10, 24, 48, 72, 96 hours after transfusion of the marked and sensitized red cells.
  • the blood sample taken 3 minutes after the red blood cell transfusion represents the 100% survival of red blood cells.
  • the results presented in FIG. 6 show that in the absence of sensitization of the red cells labeled with an antibody, the decrease in radioactivity measured over a period greater than 100 h, is less than 20%.
  • the red cells are sensitized by a therapeutic preparation of polyclonal antibodies or by the monoclonal antibody EMAB2
  • the blood radioactivity decreases rapidly; ten hours after the injection, less than 10%> of the radioactivity injected remains.
  • the disappearance curve of red cells sensitized by the monoclonal antibody EMAB2 has a profile similar to that of red blood cells sensitized by the therapeutic preparation of Rhophylac TM polyclonal antibodies.
  • the monoclonal antibody EMAB2 has an in vivo activity with respect to the clearance of pre-sensitized Rh (D +) red cells, at least comparable to that of a therapeutic polyclonal antibody preparation.
  • the anti-HLA DR antibody used in this study originates from the chimerization of the mouse antibody, of the IgG2a isotype, expressed by the Lym-1 hybridoma (ATCC Hb-8612).
  • RNA extracted from the murine antibody producing hybridoma was converted to cDNA.
  • the murine NK region was amplified using the primers K-Lym- ⁇ otl and K- Lym-Dra3 then cloned into the chimerization vector CK-Hu, previously digested by Notl and Dra3, which contains the CK sequence of a human anti-D antibody and the DHFR selection gene.
  • the murine VH region was amplified using the primers H-Lym-Not 1 and H-Lym-Apa 1 and then cloned into the Gl-Hu chimerization vector, previously digested with Not 1 and Apa 1, which contains the sequence Gl of a human anti-D antibody and the NEO selection gene.
  • the RSN promoter present in the expression vectors described above, was deleted by double digestion Bgl II and Spe I then replaced by the fragment ⁇ he I- Acc65 I.
  • the 2 clones selected are YB2 / 0-DR-4B7 for the YB2 / 0 expression cell line and DXB11-DR-22A10 for the CHO-DXB11 expression cell line.
  • the clone YB2 / 0-DR-4B7 was cultured in a 10 liter cytocultor (Biolafitte) in EM-SF1.1 medium, EMS base medium supplemented with Insulin (l ⁇ g / ml), Iron Citrate (50 ⁇ g / ml ), HEPES (4 mg / ml) and Pluronic F68 (0.5 mg / ml).
  • the DXB11-DR-22A10 clone was cultured in a 10 liter cytocultor (Biolafitte) in CHO SFM4 utility medium (Perbio) supplemented with 2% hypoxanthine. When the cell viability is less than 50%, the culture media are collected, centrifuged to remove the cells and the chimeric antibodies contained in the supernatants are purified by affinity chromatography on Sepharose-protein A.
  • the chimeric anti-HLA DR antibodies were dialyzed against a 50 mM sodium acetate buffer, pH 5.50 containing 4 mM CaC12.
  • the antibodies are degalactosylated by incubation in the presence of 5 mU of neuraminidase (EC 3.2.1.18) from Vibrio cholerae (Calbiochem) and 9 mU of ⁇ -galactosidase (EC 3.2.1.23) produced by E. Coli (Roche).
  • the control consists of the same antibody treated as indicated above but in the absence of neuraminidase and of ⁇ -galactosidase. After 24 hours of incubation at 37 ° C, the antibodies are stored at 4 ° C.
  • the antibodies generated in this example are separated into two fractions; one of the fractions is used for glycan analysis and the other fraction is reserved for the measurement of functional activity. 3. Measurement of CD16 activation
  • the Raji cell line is used as a target because it carries on its surface the antigenic determinant of the major histocompatibility complex HLA-DR.
  • 50 ⁇ l of antibody dilutions, 50 ⁇ l of a Raji cell suspension at 6.10 5 / ml, 50 ⁇ l of a suspension, Jurkat CD 16 to 1.10 6 cells are successively deposited in a 96-well microtiter plate. / ml and 50 ⁇ l of a PMA solution at 40 ng / ml. All dilutions were carried out in EMS culture medium containing 5% SNF.
  • the microtiter plate After 16 hours of incubation at 37 ° C and 7% CO 2, the microtiter plate is centrifuged and the amount of IL-2 contained in the supernatant is assayed by a commercial kit (Duoset, R&D). The levels of secreted IL-2 are expressed in pg / ml. The results are expressed in% of CD16 activation, the level of IL-2 secreted in the presence of the control monoclonal antibody being considered equal to 100%.
  • the chimeric anti-HLA DR antibodies have very different glycan structures depending on whether they are expressed by the line YB2 / 0 or CHO DXB11.
  • the ratio of fucose rate / galactose rate of the antibody expressed by YB2 / 0 is equal to 0.37 while the ratio of the antibody expressed in CHO is very increased, since it is equal to 1.3.
  • the CD 16 activation of native antibodies is in agreement with the values of fucose / galactose rate ratio; thus, the secretion of IL-2 induced by the anti-HLA DR antibody synthesized by YB2 / 0 and which has a ratio of 0.37 is 2 times greater than that induced by the same antibody synthesized by CHO DXBl 1 but whose ratio is equal to 1.3.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP04805250A 2003-10-20 2004-10-20 Correlation du ratio taux de fucose / taux de galactose d'anticorps anti rhesus d et anti hla-dr avec l'activite adcc Withdrawn EP1675873A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0312229A FR2861080B1 (fr) 2003-10-20 2003-10-20 Anticorps presentant un taux de fucose et de galactose optimise
PCT/FR2004/002686 WO2005040221A1 (fr) 2003-10-20 2004-10-20 Correlation du ratio taux de fucose / taux de galactose d’anticorps anti rhesus d et anti hla-dr avec l’activite adcc

Publications (1)

Publication Number Publication Date
EP1675873A1 true EP1675873A1 (fr) 2006-07-05

Family

ID=34385294

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04805250A Withdrawn EP1675873A1 (fr) 2003-10-20 2004-10-20 Correlation du ratio taux de fucose / taux de galactose d'anticorps anti rhesus d et anti hla-dr avec l'activite adcc

Country Status (9)

Country Link
US (1) US20070015239A1 (enExample)
EP (1) EP1675873A1 (enExample)
JP (1) JP2007533299A (enExample)
AU (1) AU2004283924B2 (enExample)
BR (1) BRPI0415565A (enExample)
CA (1) CA2542881A1 (enExample)
FR (1) FR2861080B1 (enExample)
IL (1) IL174896A0 (enExample)
WO (1) WO2005040221A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
AU2013203482B2 (en) * 2006-09-10 2015-08-27 Glycotope Gmbh Fully human high yield production system for improved antibodies and proteins
HRP20150307T1 (hr) * 2006-09-10 2015-04-24 Glycotope Gmbh Upotreba ljudskih stanica podrijetlom iz ljudske leukemije za eksprimiranje protutijela
US7846434B2 (en) * 2006-10-24 2010-12-07 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
EP1920781B1 (en) * 2006-11-10 2015-03-04 Glycotope GmbH Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
US20080227669A1 (en) * 2007-03-12 2008-09-18 Halliburton Energy Services, Inc. Corrosion-inhibiting additives, treatment fluids, and associated methods
EP1995309A1 (en) * 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
US8080415B2 (en) 2008-09-26 2011-12-20 Eureka Therapeutics, Inc. Modified host cells and uses thereof
AU2010233994A1 (en) * 2009-04-07 2011-09-22 Roche Glycart Ag Bispecific anti-ErbB-3/anti-c-Met antibodies
HUE033758T2 (en) 2009-10-26 2017-12-28 Hoffmann La Roche A method for producing glycosylated immunoglobulin
EP2374816B1 (en) 2010-04-07 2016-09-28 Agency For Science, Technology And Research Binding molecules against Chikungunya virus and uses thereof
WO2011124635A1 (en) 2010-04-07 2011-10-13 Humalys Binding molecules against chikungunya virus and uses thereof
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409989A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Method to improve glycosylation profile for antibody
JPWO2012105699A1 (ja) * 2011-02-03 2014-07-03 株式会社イーベック 補体依存性生物活性の高い抗体の産生法
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
BR112014003110A2 (pt) * 2011-08-10 2018-10-09 Lab Francais Du Fractionnement composição, método para produção de uma população altamente galactosilada de anticorpos, células epiteliais de glândula mamária e mamífero não humano tramsgênico
BR112014004065A2 (pt) 2011-08-22 2017-03-14 Glycotope Gmbh micro-organismos carregando um antígeno de tumor
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
AR094781A1 (es) * 2013-02-13 2015-08-26 Laboratoire Français Du Fractionnement Et Des Biotechnologies Anticuerpos anti-her2 (receptor 2 del factor de crecimiento epidérmico humano) altamente galactosilados y sus usos
BR112015019341A2 (pt) * 2013-02-13 2017-08-22 Lab Francais Du Fractionnement Anticorpo anti-tnf-alfa, composição que compreende o anticorpo, método para produzir uma população de anticorpos, células epiteliais da glândula mamária, mamífero não humano transgênico, e, composição de anticorpo anti-tnf monoclonal
EP2956003A2 (en) 2013-02-13 2015-12-23 Laboratoire Français du Fractionnement et des Biotechnologies Proteins with modified glycosylation and methods of production thereof
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CN114181312A (zh) * 2014-09-10 2022-03-15 豪夫迈·罗氏有限公司 半乳糖改造的免疫球蛋白1抗体
FR3035879B1 (fr) * 2015-05-07 2025-02-28 Lab Francais Du Fractionnement Mutants fc a activite fonctionnelle modifiee
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
EP3410849B1 (en) 2016-02-05 2023-07-05 Institut Pasteur Use of inhibitors of adam12 as adjuvants in tumor therapies
CN110945028B (zh) 2017-07-10 2023-09-08 国际药物发展生物技术公司 用非岩藻糖基化促凋亡抗cd19抗体与抗cd20抗体或化疗剂联合治疗b细胞恶性肿瘤
EP3508499A1 (en) 2018-01-08 2019-07-10 iOmx Therapeutics AG Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof
BR112020023373A2 (pt) 2018-05-18 2021-02-09 Daiichi Sankyo Company, Limited conjugado, composição, e, uso de um conjugado ou de uma composição
US20220372138A1 (en) 2019-07-05 2022-11-24 Iomx Therapeutics Ag Antibodies binding igc2 of igsf11 (vsig3) and uses thereof
EP3822288A1 (en) 2019-11-18 2021-05-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
EP4175668A1 (en) 2020-07-06 2023-05-10 iOmx Therapeutics AG Antibodies binding igv of igsf11 (vsig3) and uses thereof
EP4491230A1 (en) 2023-07-14 2025-01-15 iOmx Therapeutics AG Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof
IL321673A (en) 2022-12-23 2025-08-01 Iomx Therapeutics Ag LILRB1 and LILRB2 antigen-binding cross-specific proteins, their combinations and uses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0316463A1 (en) * 1987-11-13 1989-05-24 Northwestern University Murine hybridoma lym-1 and diagnostic antibody produced thereby
SE9203479L (sv) * 1992-01-20 1993-07-21 Rso Corp Saett och anordning vid elektronisk identifiering
FR2776096B1 (fr) * 1998-03-12 2000-06-23 Commissariat Energie Atomique Procede et systeme de lecture d'un ensemble dynamique d'etiquettes portant des codes d'identification distincts
FR2805637B1 (fr) * 2000-02-25 2002-12-13 Commissariat Energie Atomique Procede de lecture d'etiquettes electroniques par identification simultanee de leur code
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
WO2004047000A2 (en) * 2002-11-15 2004-06-03 Sensitech Inc. Rf identification tag for communicating condition information associated with an item
FR2859843B1 (fr) * 2003-09-16 2005-12-23 Commissariat Energie Atomique Dispositif adressable par radiofrequence, systeme comportant une pluralite de tels dispositifs agences dans l'espace et procede d'adressage par activation d'un mode transparent

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
B. M. KUMPEL: "Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers", VOX SANGUINIS, vol. 93, no. 2, 1 August 2007 (2007-08-01), pages 99 - 111, XP055002584, ISSN: 0042-9007, DOI: 10.1111/j.1423-0410.2007.00945.x *
MORI KATSUHIRO ET AL: "Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies.", CYTOTECHNOLOGY DEC 2007 LNKD- PUBMED:19003000, vol. 55, no. 2-3, December 2007 (2007-12-01), pages 109 - 114, XP019550382, ISSN: 0920-9069 *
See also references of WO2005040221A1 *

Also Published As

Publication number Publication date
CA2542881A1 (fr) 2005-05-06
WO2005040221A1 (fr) 2005-05-06
AU2004283924B2 (en) 2010-12-02
BRPI0415565A (pt) 2007-01-02
IL174896A0 (en) 2006-08-20
FR2861080A1 (fr) 2005-04-22
FR2861080B1 (fr) 2006-02-17
JP2007533299A (ja) 2007-11-22
US20070015239A1 (en) 2007-01-18
AU2004283924A1 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
EP1675873A1 (fr) Correlation du ratio taux de fucose / taux de galactose d'anticorps anti rhesus d et anti hla-dr avec l'activite adcc
Vattepu et al. Sialylation as an important regulator of antibody function
Jefferis Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action
US20220162290A1 (en) Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
US20210101961A1 (en) Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
US20080206246A1 (en) Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20120134988A1 (en) Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
WO2003084570A1 (en) DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
JP6480926B2 (ja) タンパク質におけるフコシル化レベルを制御するための方法
WO2007011041A1 (ja) 遺伝子組換え抗体組成物
WO2007146847A2 (en) Glycosylation engineered antibody therapy
Jefferis Glyco-engineering of human IgG-Fc to modulate biologic activities
US20130217863A1 (en) Method to Improve Glycosylation Profile and to Induce Maximal Cytotoxicity for Antibody
Mimura et al. Importance and monitoring of therapeutic immunoglobulin G glycosylation
WO2007080277A1 (fr) Procede de preparation d' anticorps selectifs des recepteurs fc activateurs
CA2666308A1 (en) Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP1537419B1 (fr) Procédé d'évaluation de l'efficacité ADCC médiée par le CD16 d'anticorps monoclonaux ou polyclonaux
NZ597651A (en) Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
Nimmerjahn Role of Antibody Glycosylation in Health, Disease, and Therapy
US20110150867A1 (en) Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
CN101466402A (zh) 糖基化改造的抗体治疗
FR2861079A1 (fr) Utilisation de cations metalliques divalents pour l'amelioration de l'activite fonctionnelle des anticorps.
Jefferis Antibody posttranslational modifications

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060331

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: LFB BIOTECHNOLOGIES

17Q First examination report despatched

Effective date: 20081009

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20111104